N | 9 |
---|---|
Age, y | 58 ± 8.4 |
Men | 8 (89%) |
Body mass index (kg/m2) | 29 ± 4.1 |
Tumor location at initial diagnosis—N (%) | |
Esophagus | 8 (89%) |
Gastroesophageal junction | 1 (11%) |
Histologic type—N (%) | |
Adenocarcinoma | 6 (67%) |
Squamous cell carcinoma | 3 (33%) |
Pathological lymph node status—N (%) | |
ypN0 | 1 (11%) |
≥ ypN1 | 3 (33%) |
pN0 | 3 (33%) |
≥ pN1 | 0 |
Not known | 2 (22%) |
Pathological tumor status—N (%) | |
ypT0 | 1 (11%) |
ypT1 or ypT2 | 0 |
ypT3 or ypT4 | 3 (33%) |
pT0 | 0 |
pT1 or pT2 | 2 (22%) |
pT3 or pT4 | 1 (11%) |
Not known | 2 (22%) |
Histologic grade | |
1 or 2 | 8 (89%) |
3 or 4 | 1 (11%) |
Not assessed | 0 |
Tumor-cell PD-L1 expression—N (%) | |
< 1% | 0 |
≥ 1% | 2 (22%) |
Indeterminate or could not be evaluated | 7 (78%) |
HER2 status | |
Positive | 0 |
Negative | 5 (56%) |
Not reported | 4 (44%) |
ECOG performance-status score—N (%) * | |
0 | 6 (67%) |
1 | 3 (33%) |